Technology | Genetic Testing | October 08, 2015

Invitae Expands Cardiology Genetic Testing Offerings

Testing menu now covers more than 190 genes for a variety of hereditary cardiovascular disorders

Invitae Corp., cardiovascular test panels, genetic testing, expands offerings

October 8, 2015 — Invitae Corp., a genetic information company, announced the expansion of its cardiology offering, including more than 30 cardiovascular test panels for arrhythmias, cardiomyopathies, aortopathies, familial hypercholesterolemia, pulmonary hypertension and congenital heart disease. 

Genetic cardiac conditions may be difficult to diagnose. Often, the first evidence of a hereditary cardiac condition is the sudden death of an otherwise healthy person, sometimes in infancy or childhood. Invitae’s expanded cardiovascular test menu allows the company to provide first-line genetic testing for inherited arrhythmia and cardiomyopathy conditions, including sudden cardiac arrest or death, as well as inherited aortic diseases and familial hypercholesterolemia, one of the most common inherited cardiovascular conditions. This comprehensive cardiology offering includes a rigorous, evidence-based variant classification process developed by a team of board-certified genetic counselors, Ph.D. scientists, and physicians with special expertise in the genetic testing for hereditary cardiovascular disorders. 

“Heart disease is the number one cause of death in our country, and there are a number of red flags that could indicate when there’s genetic heart disease in the family,” said Amy Sturm, MS, LCGC, associate professor and genetic counseling expert at the Ohio State University. 

Sturm encourages everyone to pay attention to the following types of events in their family health history: 

  • A relative diagnosed with heart disease at an early age;
  • Multiple family members who have had a heart attack, an abnormal heart rhythm, heart failure or a heart transplant; and
  • A relative who died suddenly or had an unexplained death. 

With this offering, Invitae’s cardiology menu will expand to more than 190 genes. Clinicians can easily choose the right test for their patient, with no penalty for starting with large or small panels, because of Invitae’s policies of charging a flat price per indication — regardless of the number of genes ordered — as well as allowing physicians to re-requisition additional genes for the same condition within 90 days for no additional charge. 

According to patient advocacy organization the Sudden Arrhythmia Death Syndromes (SADS) Foundation, making testing more accessible is key. “We believe that with genetic information families can better understand their genetic risks and when necessary, take preventive action,” the organization stated in their recent newsletter. “Lowering costs of testing and making tests easier to get will help families everywhere. We believe that by working to make these genetic tests more available and affordable we are giving families information that will help save lives.” 

Invitae offers a transparent pricing structure independent of the number of genes required to provide an accurate diagnosis for any specific clinical indication. For payers and institutions who are in contract with Invitae, the price per indication can be as low as $950, depending on the payer’s requirements. For third-party payers with whom Invitae is out of network and for non-contracted institutions, the price per indication remains $1,500. In addition, for patients without third-party insurance coverage or who do not meet insurance criteria for coverage, Invitae offers its full test menu for $475 per indication for patients whose clinician has ordered the testing online and who register online and pay in advance for the testing. 

For more information: www.ir.invitae.com

Related Content

NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
PURE study may cause revision of fat intake guidelines for cardiology.
Feature | ESC| September 07, 2017
September 7, 2017 — Researchers at the European Society of Cardiology (ESC) Congress called for a reconsideration of
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Advances in FFR, FFR-CT, was the most popular cardiology story in August 2017.

The most popular article in August was about advances in fractional flow reserve (FFR) technologies. The image shows Philips' new version of its iFR system that displays hemodynamic pressure drop points in an overlay on live angiographic images, matching up the iFR readings with corresponding lesions.

Feature | September 01, 2017 | Dave Fornell
September 1, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Car
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
Overlay Init